Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300817 · ClinicalTrials.gov registry record · Phase 1
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer
A Phase 1 study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT03300817: Active Phase 1 study of Lung Carcinoma, sponsored by National Cancer Institute (NCI).
NCT03300817 is a Phase 1 study of Lung Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 5,042-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300817, a Phase 1 study of Lung Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
Primary Outcome
Will be evaluated by monitoring changes in IgG anti-MUC1 antibody titer ratio; defined as t12/t0, where t0 is the "initial titer" measured prior to vaccination, and t12 is the "final titer" drawn at 12 weeks. A titer ratio of \>= 2 will be considered a positive response.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL MUC1 Peptide-Poly-ICLC Vaccine
Study Locations (2)
Minnesota
- Mayo Clinic in Rochester - Rochester
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 1 |
What the registry record for NCT03300817 still lists
NCT03300817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 5,042-participant average among 38 other Lung Carcinoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03300817 reports a single indexed study location in Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03300817 about?
NCT03300817 is a clinical study titled "MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer". This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine works in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-...
What is the current status of trial NCT03300817?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2017-12-27. Estimated completion is 2025-12-01.
What conditions does trial NCT03300817 study?
This clinical trial studies the following conditions: Lung Carcinoma.
What interventions are being tested in trial NCT03300817?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), MUC1 Peptide-Poly-ICLC Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03300817?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03300817 being conducted?
This trial has 2 study locations across Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03300817's enrollment target sits among peer trials
50 25th of 38 higher than 11 of 38 other Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
RECRUITING · Phase 1
-
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
-
Iloprost in Preventing Lung Cancer in Former Smokers
COMPLETED · Phase 1
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
The Rise in Robotic Atypical Segmentectomies
RECRUITING
-
Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care (Interception for Suspected Lung Cancer)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI